Merck Q3 2026 net income falls 12% year over year to $5.07 billion
MRK•Merck reported third-quarter 2026 net income of $5.07 billion, down 12% year over year, and sales of $18.09 billion, up 5%.
1. Quarterly results and outlook
Merck’s third-quarter 2026 GAAP earnings per share fell 12% year over year to $2.04, while sales rose 5% to $18.09 billion. WINREVAIR sales jumped 93% to $694 million. The FDA accepted sac-TMT for priority review in previously treated endometrial cancer, with a decision deadline of June 15, 2027. Merck narrowed its full-year 2026 sales guidance to $66.8 billion–$67.3 billion, raising the lower end from $66.3 billion.
